Clinical Characteristics of Korean Patients with Lung Cancer Who Have Programmed Death-Ligand 1 Expression

Park, Ha-Young; Oh, In-Jae; Kho, Bo Gun; Kim, Tae-Ok; Shin, Hong-Joon; Park, Cheol Kyu; Kwon, Yong-Soo; Kim, Yu-Il; Lim, Sung-Chul; Kim, Young-Chul; Choi, Yoo-Duk

추천

검색

자료유형: 학술저널

저자정보: Park, Ha-Young (Department of Internal Medicine, Chonnam National University Medical School) Oh, In-Jae (Department of Internal Medicine, Chonnam National University Medical School) Kho, Bo Gun (Department of Internal Medicine, Chonnam National University Medical School) Kim, Tae-Ok (Department of Internal Medicine, Chonnam National University Medical School) Shin, Hong-Joon (Department of Internal Medicine, Chonnam National University Medical School) Park, Cheol Kyu (Department of Internal Medicine, Chonnam National University Medical School) Kwon, Yong-Soo (Department of Internal Medicine, Chonnam National University Medical School) Kim, Yu-Il (Department of Internal Medicine, Chonnam National University Medical School) Lim, Sung-Chul (Department of Internal Medicine, Chonnam National University Medical School) Kim, Young-Chul (Department of Internal Medicine, Chonnam National University Medical School) Choi, Yoo-Duk (Lung and Esophageal Cancer Clinic, Chonnam National University Hwasun Hospital)

저널정보: 대한결핵 및 호흡기학회 Tuberculosis and Respiratory Diseases 결핵 및 호흡기 질환 제82권 제3호

발행연도: 2019.1

수록면: 227 - 233 (7page)

이용수

📌

연구주제

📖

연구배경

🔬

연구방법

🏆

연구결과

초록· 키워드

오류제보하기

Background: Programmed death-ligand 1 (PD-L1), a transmembrane protein, binds to the programmed death-1 (PD-1) receptor, and anti-PD-1 therapy enables immune responses against tumors. This study aimed to assess clinical characteristics of PD-L1 expression using immunohistochemistry among Korean patients with lung cancer. Methods: We retrospectively reviewed the data of patients with pathologically proven lung cancer from a single institution. PD-L1 expression determined by Tumor Proportion Score (TPS) was detected using 22C3 pharmDx (Agilent Technologies) and SP263 (Ventana Medical Systems) assays. Results: From July 2016 to July 2017, 267 patients were enrolled. The main histologic type was adenocarcinoma (69.3%). Most participants were smokers (67.4%) and had clinical stage IV disease (60.7%). In total, 116 (42%) and 58 (21%) patients had TPS ${\geq}1%$ and ${\geq}50%$, respectively. The patients were significantly older in TPS ${\geq}1%$ group than in TPS <1% group ($64.83{\pm}9.38years$ vs. $61.73{\pm}10.78years$, p=0.014), not in TPS ${\geq}50%$ cutoff value ($64.69{\pm}9.39$ vs. $62.36{\pm}10.51$, p=0.178). Regarding histologic grade, higher proportions of poorly differentiated tumor were observed in the TPS ${\geq}1%$ (40.8% vs. 25.8%, p=0.020) and TPS ${\geq}50%$ groups (53.2% vs. 27.2%, p=0.004). Among 34 patients examined with 22C3 and SP263 assays, 27 had positive results in both assays, with a cutoff of TPS ${\geq}1%$ (r=0.826; 95% confidence interval, 0.736-0.916). Conclusion: PD-L1 expression, defined as TPS ${\geq}1%$, was related to older age and poorly differentiated histology. There was a similar distribution of PD-L1 expression in both 22C3 and SP263 results.

#Asian Continental Ancestry Group #Patients #Lung Neoplasms #Gene Expression #Carcinoma, Non-Small-Cell Lung

참고문헌 (0)

참고문헌 신청

참고문헌이 DBpia에서 서비스 중이라면, [참고문헌 신청]을 통해 등록해보세요

함께 읽어보면 좋을 논문

논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!